| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3879767 | The Journal of Urology | 2006 | 6 Pages |
Abstract
The gonadotropin hormone-releasing hormone agonist histrelin acetate provided in a unique implant delivery device is effective for treating men with advanced prostate cancer, as demonstrated by the suppression of testosterone and LH to castrate levels at 4 weeks and the maintenance of these levels during 52 weeks. PSA, a secondary end point for effectiveness, was also suppressed significantly from baseline.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Peter N. Schlegel, Histrelin Study Group Histrelin Study Group,